The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
Amazon's recent workforce reductions, bringing total corporate cuts to 30,000, reflect a broader shift in how layoffs are perceived. No longer framed as a sign of failure, they are increasingly presented as a strategic, forward-looking move to streamline operations and focus on priorities like AI, a narrative that resonates with investors despite the human impact.
A growing movement to eliminate state income taxes is gaining momentum, backed by the White House. However, a new analysis warns that replacing lost revenue may require significantly higher sales taxes than proponents claim, forcing a fundamental choice: accept steeper consumption taxes or shrink the size of government.
A 15-day blackout of ESPN networks on YouTube TV last fall carved a $110 million hole in the sports giant's quarterly operating income, new financial disclosures reveal. The dispute underscores the high-stakes brinkmanship now defining relationships between content owners and distribution platforms.
South Korean financial regulators are deploying advanced artificial intelligence to monitor cryptocurrency transactions in real-time, aiming to detect and preempt market manipulation. The move, part of a broader crackdown, could see violators face severe penalties, including life imprisonment.
A coalition of licensed marijuana companies in Missouri has launched a wave of lawsuits against dozens of smoke shops, alleging they are exploiting a legal gray area to sell intoxicating THCA hemp flower, undermining the state's regulated market and creating unfair competition.
A landmark tripartite agreement between financial heavyweight Schroders, battery leader CATL, and investment firm Lochpine Capital aims to deploy up to 10GWh of energy storage across Europe, marking a significant step in the continent's clean energy transition.
Analysts at Piper Sandler have increased their price target for Permian Basin-focused producer Diamondback Energy (FANG) to $218, maintaining an Overweight rating. The move comes as the firm anticipates solid Q4 results for gas-focused companies, while oil producers navigate a tougher pricing environment.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Barclays raises its price target on NorthWestern Energy Group (NWE) to $62, citing solid quarterly performance and strategic moves, including a pending merger with Black Hills Corporation, as the regulated utility reaffirms its long-term growth outlook.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.
CIBC lowers OpenText's price target to $37, citing softer guidance and a watchful stance on the company's planned divestiture of non-core assets to sharpen its AI focus.
Warren Buffett once admitted that managing a smaller pool of capital can be a 'huge structural advantage.' For retail investors, this isn't just theory—it's a practical edge in accessing high-growth opportunities that are now out of reach for the investing giant.
Disney's first fiscal quarter of 2026 saw revenue climb to $25.98 billion, buoyed by record theme park sales and blockbuster films. While streaming income surged dramatically, the company has followed Netflix's lead in ceasing public reporting of Disney+ and Hulu subscriber numbers, shifting investor focus to profitability.
A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
While a recent executive order aims to streamline AI rules, experts caution that customer experience teams face a complex transition—not a regulatory holiday—demanding stronger internal governance.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
After a historic surge, gold prices have experienced their steepest drop in decades. Yet, analysts point to enduring geopolitical tensions and monetary policy shifts as reasons why the metal's long-term appeal remains intact.
Amid a choppy market landscape in early 2026, value investors are scanning for opportunities. We analyze three companies—Viavi Solutions, Kontoor Brands, and Robert Half—whose current share prices appear significantly disconnected from their estimated intrinsic worth based on cash flow projections.
